Monitoring bypassing agent therapy - a prospective crossover study comparing thromboelastometry and XXXX generation assay.

@entity1 @entity556 @entity447
UNASSIGNED: The aim of this study was to evaluate the capability of thromboelastometry (ROTEM) and @entity556 generation assay (TGA) to monitor the treatment response of bypassing agent (BPA) therapy and to study whether one method is superior to another. In a prospective crossover study @entity447 @entity1 with high titre inhibitors were included to receive a dose of 75  U  kg(-1) activated prothrombin complex concentrates (aPCC) intravenously. Blood sampling was performed at baseline, 15, 30  min, 1, 2, 3 and 4  h post-infusion for TGA and ROTEM analysis. After a washout period of 14  days the subjects received recombinant FVIIa (rFVIIa) at a dose of 90   g  kg(-1) and similar blood sampling was performed. Healthy subjects were used as controls. Six @entity447 @entity1 with inhibitors were included. We found that TGA parameters endogenous @entity556 potential (ETP) and peak @entity556 increased 2-3 folds from baseline 15-30  min after infusion. ROTEM parameters MaxVel and maximum clot firmness increased to a level comparable to that of healthy controls. An individual difference in response was observed for different parameters among @entity1 . ETP and peak @entity556 were almost two-fold greater following aPCC infusion compared to rFVIIa, whereas ROTEM parameters showed no difference in response between the two products. The study showed that ROTEM and TGA have a great potential to evaluate the effect of BPA in @entity447 @entity1 with inhibitors. TGA seemed to be more sensitive than ROTEM in reflecting the difference in treatment response between aPCC and rFVIIa. Additional prospective clinical studies are needed to clarify which assay and what parameters are clinically predictive.
